ICI delisting ends bad month for US markets

NEW YORK - The role the Sarbanes-Oxley Act (Sox) is playing in driving firms away from public listings in the US has been thrown into the spotlight once again, after a bad month saw a wave of foreign firms flee the American capital markets.


British chemical company ICI announced on May 29 its intent to scrap its secondary exchange listing in the US, citing the cost of regulation as the key factor in its decision.


“It no longer makes sense from a cost and administrative perspective to submit

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: